Eyenovia, Inc. (NASDAQ:EYEN – Get Free Report) was the target of a significant decline in short interest during the month of August. As of August 15th, there was short interest totalling 1,440,000 shares, a decline of 6.5% from the July 31st total of 1,540,000 shares. Based on an average daily volume of 370,000 shares, the short-interest ratio is currently 3.9 days.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Eyenovia in a research note on Friday, August 18th.
Insiders Place Their Bets
Hedge Funds Weigh In On Eyenovia
Institutional investors have recently bought and sold shares of the stock. Two Sigma Securities LLC bought a new position in Eyenovia in the second quarter worth about $27,000. Virtu Financial LLC bought a new position in Eyenovia in the fourth quarter worth about $26,000. American International Group Inc. bought a new position in Eyenovia in the second quarter worth about $32,000. Meitav Investment House Ltd. bought a new position in Eyenovia in the second quarter worth about $1,104,000. Finally, Oak Family Advisors LLC raised its stake in Eyenovia by 36.9% in the second quarter. Oak Family Advisors LLC now owns 61,146 shares of the company’s stock worth $145,000 after buying an additional 16,485 shares in the last quarter. 16.66% of the stock is owned by institutional investors.
Eyenovia Stock Performance
Shares of NASDAQ:EYEN opened at $1.95 on Friday. The company has a market cap of $74.51 million, a price-to-earnings ratio of -2.83 and a beta of 1.64. The company has a 50-day moving average price of $2.16 and a 200-day moving average price of $2.98. The company has a current ratio of 5.73, a quick ratio of 5.73 and a debt-to-equity ratio of 1.25. Eyenovia has a 12 month low of $1.50 and a 12 month high of $5.85.
Eyenovia (NASDAQ:EYEN – Get Free Report) last issued its quarterly earnings data on Thursday, August 10th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.04. As a group, equities analysts anticipate that Eyenovia will post -0.69 EPS for the current year.
Eyenovia, Inc, a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system.
- Five stocks we like better than Eyenovia
- How Investors Can Find the Best Cheap Dividend Stocks
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- Trading Stocks: RSI and Why it’s Useful
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
- How to Invest in Canada for Beginners
- 5 Critical Takeaways From MongoDB’s Q2 Results for AI Investors
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.